Arcus Biosciences Inc. (RCUS)
NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RCUS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.25B
- EPS (TTM)
- -$3.64
- Dividend yield
- None
- 52-week range
- 15.56 – 31.74
- Day range
- 15.56 – 16.66
- Volume / Avg
- 1.67M / 1.85M
- Beta
- —
- Shares outstanding
- 143.99M
52-week range
RCUS stock today
Arcus Biosciences (RCUS) closed at $15.62 on Nov 20, down 1.01% (-$0.16), versus the S&P 500's 3.70% decline. Shares are 50.8% below their 52-week high of $31.74, set on Jun 30, 2026 and 0.4% above the 52-week low of $15.56, near the bottom of the past year's range. RCUS is down 34.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 29.2%.
Arcus Biosciences has posted a net loss over the last twelve months (EPS of -$3.64), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Arcus Biosciences
Company profileArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Terry J. Rosen Ph.D.
- Headquarters
- Hayward, CA
- Employees
- 601
- IPO year
- 2018
- Website
- arcusbio.com
Financial highlights
Full financialsIn fiscal 2025, Arcus Biosciences generated $247.0 million in revenue, down 4.3% from fiscal 2024, its first annual decline since 2022. Arcus Biosciences reported a net loss of $353.0 million, compared with a loss of $283.0 million a year earlier. Operating margin was -156.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $247.00M | $258.00M | $117.00M | $112.00M | $383.00M |
| Growth | -4.26% | +120.51% | +4.46% | -70.76% | +391.03% |
| Net income | $-353.00M | $-283.00M | $-307.00M | $-267.00M | $53.00M |
| EPS (diluted) | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$41.00+162.48%
- Strong buy 1
- Buy 12
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-1.27 vs $-0.92
- Surprise
- -38.04%
RCUS news
All RCUS news- Arcus Biosciences, Inc. Reports Third-Quarter 2026 Financial ResultsNasdaq
- Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline UpdateBusiness Wire
- Arcus Biosciences prices $250M public offering at $17.50 per shareSeeking Alpha
- Why is Arcus Biosciences stock sliding today?Investing.com
- Arcus Biosciences, Inc. Estimates $694.0 million in Cash, Cash Equivalents and Marketable Securities as of September 30, 2026Nasdaq
- Arcus Biosciences slides 20% on stock offering, kidney-cancer dataSeeking Alpha
- Arcus Biosciences stock falls on public offering announcementInvesting.com
- Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law FirmPR Newswire
Arcus Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HCMHUTCHMED (China) Limited ADR | 13.22 | -1.71% | $2.30B | vs RCUS |
| PHVSPharvaris N.V. | 31.28 | -1.20% | $2.21B | vs RCUS |
| PRGOPerrigo Company plc | 15.94 | -0.62% | $2.21B | vs RCUS |
| NAMSNewAmsterdam Pharma Company N.V. | 18.41 | -5.64% | $2.21B | vs RCUS |
| PBHPrestige Consumer Healthcare Inc. | 49.63 | +0.06% | $2.35B | vs RCUS |
| LKFTLakefront Biotherapeutics ADR | 33.31 | -0.24% | $2.18B | vs RCUS |
| PVLAPalvella Therapeutics Inc. | 142.85 | -2.00% | $2.09B | vs RCUS |
| MBXMBX Biosciences Inc. | 49.55 | -7.23% | $2.46B | vs RCUS |
Indexes, lists and sector
Arcus Biosciences stock FAQ
What is Arcus Biosciences's stock price today?
RCUS last traded at $15.62 as of Nov 20, 4:00 PM EST, down 1.01% on the day. Prices are delayed at least 15 minutes.
Who is Arcus Biosciences's CEO?
Dr. Terry J. Rosen Ph.D. is the chief executive officer of Arcus Biosciences Inc., which has about 601 employees.
What is the RCUS 52-week high?
The 52-week high for RCUS is $31.74 and the 52-week low is $15.56. The stock is currently 50.8% below its high.